April 7th 2025
Enrollment for the Phase II trial follows FDA clearance of SPG302 Investigational New Drug application for schizophrenia.
2023 Pipeline Report: Testing the Limits
December 8th 2022Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
September 9th 2022Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
Milestones and Momentum: Assessing Advancements in Personalized Medicine
August 10th 2022The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.